---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/100000000862350.md"
description: "The +177% rally in $Moderna is a massive clinical milestone for mRNA tech, but chasing a parabolic move at this level carries significant downside risk.While long-term growth for oncology mRNA therapies with $Merck looks promising, short-term profit taking and insider selling are real risks after such a huge leap. I’d rather sit this initial surge out and wait for a healthy pullback to build a position safely."
datetime: "2026-08-20T06:25:34.000Z"
locales:
  - [en](https://longbridge.com/en/topics/100000000862350.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/100000000862350.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/100000000862350.md)
author: "[Lemonade](https://longbridge.com/en/profiles/22811857.md)"
generator: "portal-rs"
---

# The +177% rally in $Moderna is a massive clinical …


### Related Stocks

- [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md)
- [MRK.US](https://longbridge.com/en/quote/MRK.US.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**